Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics

OBJECTIVES: With the wide range of biological disease-modifying anti-rheumatic drugs (bDMARDs) available for treating rheumatoid arthritis (RA), and limited evidence to guide the choice for individual patients, we wished to evaluate whether patient characteristics influence the choice of bDMARD in c...

Descripción completa

Detalles Bibliográficos
Autores principales: Frisell, Thomas, Baecklund, Eva, Bengtsson, Karin, Di Giuseppe, Daniela, Forsblad-d’Elia, Helena, Askling, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909744/
https://www.ncbi.nlm.nih.gov/pubmed/29237621
http://dx.doi.org/10.1136/annrheumdis-2017-212395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909744/
https://www.ncbi.nlm.nih.gov/pubmed/29237621
http://dx.doi.org/10.1136/annrheumdis-2017-212395

Ejemplares similares